Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of hepatoxicity and teratogenicity for patie...
Used in the treatment of relapsing forms of multiple sclerosis (MS).
Investigational Site Number 040001, Wien, Austria
Investigational Site Number 124002, London, Canada
Investigational Site Number 124003, Greenfield Park, Canada
Investigational Site Number 170001, Barranquilla, Colombia
Investigational Site Number 170007, Bogota, Colombia
Investigational Site Number 233002, Tallinn, Estonia
Investigational Site Number 056003, Bruxelles, Belgium
Investigational Site Number 056001, Gent, Belgium
Investigational Site Number 203004, Jihlava, Czech Republic
Sanofi-Aventis Administrative Office, Guildford, United Kingdom
Sanofi-Aventis Investigational Site Number 840020, Charleston, West Virginia, United States
Sanofi-Aventis Investigational Site Number 840060, Syracuse, New York, United States
Sanofi-Aventis Investigational Site Number 840078, Dayton, Ohio, United States
Investigational Site Number 5307, Sofia, Bulgaria
Investigational Site Number 1405, Geelong, Australia
Investigational Site Number 8953, St. Petersburg, Florida, United States
Sanofi-Aventis Administrative Office, Barcelona, Spain
Sanofi-Aventis Administrative Office, Guildford, United Kingdom
sanofi-aventis, Canada, Laval, Canada
Sanofi-Aventis, Bromma, Sweden
Sanofi-Aventis Deutschland GmbH, Berlin, Germany
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.